U.S. flag

An official website of the United States government

NM_000251.3(MSH2):c.2039G>C (p.Arg680Pro) AND Hereditary cancer-predisposing syndrome

Germline classification:
Pathogenic (1 submission)
Last evaluated:
May 23, 2022
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000568876.4

Allele description [Variation Report for NM_000251.3(MSH2):c.2039G>C (p.Arg680Pro)]

NM_000251.3(MSH2):c.2039G>C (p.Arg680Pro)

Gene:
MSH2:mutS homolog 2 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
2p21
Genomic location:
Preferred name:
NM_000251.3(MSH2):c.2039G>C (p.Arg680Pro)
HGVS:
  • NC_000002.12:g.47476400G>C
  • NG_007110.2:g.78277G>C
  • NM_000251.3:c.2039G>CMANE SELECT
  • NM_001258281.1:c.1841G>C
  • NP_000242.1:p.Arg680Pro
  • NP_001245210.1:p.Arg614Pro
  • LRG_218:g.78277G>C
  • NC_000002.11:g.47703539G>C
  • NM_000251.1:c.2039G>C
Protein change:
R614P
Links:
dbSNP: rs1203462814
NCBI 1000 Genomes Browser:
rs1203462814
Molecular consequence:
  • NM_000251.3:c.2039G>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001258281.1:c.1841G>C - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Hereditary cancer-predisposing syndrome
Synonyms:
Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000669776Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)
Pathogenic
(May 23, 2022)
germlineclinical testing

PubMed (5)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Mechanism of mismatch recognition revealed by human MutSβ bound to unpaired DNA loops.

Gupta S, Gellert M, Yang W.

Nat Struct Mol Biol. 2011 Dec 18;19(1):72-8. doi: 10.1038/nsmb.2175.

PubMed [citation]
PMID:
22179786
PMCID:
PMC3252464

UMD-MLH1/MSH2/MSH6 databases: description and analysis of genetic variations in French Lynch syndrome families.

Grandval P, Fabre AJ, Gaildrat P, Baert-Desurmont S, Buisine MP, Ferrari A, Wang Q, Béroud C, Olschwang S.

Database (Oxford). 2013 May 31;2013:bat036. doi: 10.1093/database/bat036. Print 2013.

PubMed [citation]
PMID:
23729658
PMCID:
PMC3668602
See all PubMed Citations (5)

Details of each submission

From Ambry Genetics, SCV000669776.5

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (5)

Description

The p.R680P variant (also known as c.2039G>C), located in coding exon 13 of the MSH2 gene, results from a G to C substitution at nucleotide position 2039. The arginine at codon 680 is replaced by proline, an amino acid with dissimilar properties. This alteration has been previously identified in a family with suspected Lynch syndrome (Bonadona V et al. JAMA. 2011 Jun 8;305(22):2304-10), in families that met Amsterdam I/II criteria for Lynch syndrome, and in individuals whose tumors demonstrated high microsatellite stability and/or absent MSH2/MSH6 staining on immunohistochemistry (Ambry internal data; Grandval P et al. Database (Oxford), 2013 May;2013:bat036; Xu Y et al. Front Genet, 2020 Aug;11:991). Based on internal structural analysis, this variant is anticipated to result in a significant disruption in ATP binding (Gupta S et al. Nat. Struct. Mol. Biol., 2011 Dec;19:72-8). In a massively parallel cell-based functional assay testing susceptibility to a DNA damaging agent, 6-thioguanine (6-TG), this variant was reported to be functionally deleterious (Jia X et al. Am J Hum Genet, 2021 01;108:163-175). The yeast equivalent of this variant demonstrated an increased mutation rate in a multiplexed functional assay performed using Saccharomyces cerevisiae (Ollodart AR et al. Genetics, 2021 06;218:). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024